- Home
- DUO vs APLM Comparison
DUO vs APLM Comparison
Compare DUO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- APLM
- Stock Information
- Founded
- DUO 2011
- APLM 2016
- Country
- DUO China
- APLM United States
- Employees
- DUO N/A
- APLM N/A
- Industry
- DUO Real Estate
- APLM Blank Checks
- Sector
- DUO Finance
- APLM Finance
- Exchange
- DUO Nasdaq
- APLM Nasdaq
- Market Cap
- DUO 6.1M
- APLM 6.1M
- IPO Year
- DUO 2019
- APLM N/A
- Fundamental
- Price
- DUO $3.44
- APLM $5.16
- Analyst Decision
- DUO
- APLM
- Analyst Count
- DUO 0
- APLM 0
- Target Price
- DUO N/A
- APLM N/A
- AVG Volume (30 Days)
- DUO 5.1M
- APLM 36.1K
- Earning Date
- DUO 08-29-2025
- APLM 09-19-2025
- Dividend Yield
- DUO N/A
- APLM N/A
- EPS Growth
- DUO N/A
- APLM N/A
- EPS
- DUO N/A
- APLM N/A
- Revenue
- DUO $56,189,313.00
- APLM $198,000.00
- Revenue This Year
- DUO N/A
- APLM $415.15
- Revenue Next Year
- DUO N/A
- APLM N/A
- P/E Ratio
- DUO N/A
- APLM N/A
- Revenue Growth
- DUO 48.30
- APLM N/A
- 52 Week Low
- DUO $1.24
- APLM $3.66
- 52 Week High
- DUO $74.72
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- DUO 73.18
- APLM 46.73
- Support Level
- DUO $1.46
- APLM $3.66
- Resistance Level
- DUO $3.25
- APLM $6.37
- Average True Range (ATR)
- DUO 0.48
- APLM 0.56
- MACD
- DUO 0.20
- APLM -0.06
- Stochastic Oscillator
- DUO 75.86
- APLM 55.37
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.